This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (43)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Surgery  • Surgery, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Howard M. Karpoff, MD; David S. Klimstra, MD; Murray F. Brennan, MD; Kevin C. Conlon, MD, MBA

Arch Surg. 2001;136:44-47.

Hypothesis  Total pancreatectomy for infiltrating ductal adenocarcinoma is not superior to pancreaticoduodenectomy or distal pancreatectomy.

Design  A retrospective analysis of a prospective database of patients.

Setting  Memorial Sloan-Kettering Cancer Center, New York, NY.

Patients  All patients (n = 488) undergoing pancreatic resection.

Main Outcome Measures  Duration of operation, estimated blood loss, complications, length of stay, number of positive lymph nodes, presence of a positive margin, and survival times were analyzed.

Results  Thirty-five patients were identified who underwent total pancreatectomy, 28 of whom had adenocarcinoma. Median length of stay was 32 days; 19 (54%) developed postoperative complications, of which 63% were infectious. Thirty-day mortality was 3% (1 patient). Median survival was 9.3 months (range, 0.6-172 months). There was no significant difference between patients with and without adenocarcinoma in terms of duration of operation, estimated blood loss, complications, length of stay, or number of readmissions. In patients with adenocarcinoma, margin or nodal status were not significant survival variables. Patients undergoing total pancreatectomy for adenocarcinoma had a significantly worse overall survival than those undergoing total pancreatectomy for other reasons (P<.001), or compared with a contemporaneous cohort with adenocarcinoma undergoing pancreaticoduodenectomy (n = 409) and distal pancreatectomy (n = 51) (7.9 vs 17.2 months; P<.002).

Conclusions  Total pancreatectomy can be performed safely with low mortality; survival is predicted by the underlying pathologic findings: patients undergoing total pancreatectomy for adenocarcinoma have a uniformly poor outcome. Those undergoing total pancreatectomy for benign disease or nonadenocarcinoma variants can have long-term survival. In patients who require total pancreatectomy for ductal adenocarcinoma, the survival is so poor as to bring into question the value of the operation.

From the Departments of Surgery (Drs Karpoff, Brennan, and Conlon) and Pathology (Dr Klimstra), Memorial Sloan-Kettering Cancer Center, New York, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Archives of Surgery Reader's Choice: Continuing Medical Education
Arch Surg. 2001;136(1):120-121.
FULL TEXT  

Results of Total Pancreatectomy for Adenocarcinoma of the Pancreas—Invited Critique
A. R. Moossa
Arch Surg. 2001;136(1):48.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Patient and Hospital Characteristics on the Variance of Perioperative Outcomes for Pancreatic Resection in the United States: A Plea for Outcome-Based and Not Volume-Based Referral Guidelines
Teh et al.
Arch Surg 2009;144:713-721.
ABSTRACT | FULL TEXT  

Extended Resection for Pancreatic Adenocarcinoma
Reddy et al.
The Oncologist 2007;12:654-663.
ABSTRACT | FULL TEXT  

An unfavourable prognosis for pancreatic cancer indicates fields of opportunity.
Greenhalf
Gut 2006;55:1533-1535.
FULL TEXT  

Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins
Kim et al.
Gut 2006;55:1598-1605.
ABSTRACT | FULL TEXT